Last reviewed · How we verify
NCT06699719
Online Writing Intervention for Major Depressive Disorder
NA trial testing Expressive writing in Major Depression in 63 participants. Completed in 14 June 2022.
14 June 2022
Quick facts
| Lead sponsor | Centre for Addiction and Mental Health |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | single group |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 63 |
| Start date | 27 March 2019 |
| Primary completion | 14 June 2022 |
| Estimated completion | 14 June 2022 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Expressive writing
Conditions studied
- Major Depression — all drugs for Major Depression →
- Generalized Anxiety Disorder (GAD) — all drugs for Generalized Anxiety Disorder (GAD) →
Sponsor
Centre for Addiction and Mental Health — full company profile →
Who can join
18 and older, any sex, with Major Depression or Generalized Anxiety Disorder (GAD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this trial is to examine the feasibility of administering an online writing intervention to patients diagnosed with Major Depressive Disorder, and whether this intervention impacts symptoms of depression. It also examines the impact of the intervention on symptoms of anxiety, personal functioning, and perceived problem complexity, and how participants experience the intervention. The main questions the trial aims to answer are: Will participants randomized to the online writing intervention complete at least three sessions? Is the writing intervention associated with a reduction in symptoms of depression and anxiety, perceived problem complexity, and/or an improvement in personal functioning? What are participants' perceptions of the online writing intervention, including both positive and negative experiences? Participants will: Complete four sessions of an online writing intervention or no writing intervention over the course of one week Complete questionnaires before and after the intervention, and at a one-month follow-up Complete qualitative interviews probing into their experiences with the intervention
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Feasibility, efficacy, and perceptions of an online writing intervention in patients with depressive disorders: A randomized, multi-methods pilot study.
Maslej MM, Ortiz A, Andrews PW, Mulsant BH. · · 2025 · PMID 41661959 · DOI 10.1371/journal.pmen.0000245
Verify or expand the search:
- PubMed search for NCT06699719
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Expressive writing
Trials testing the same drug.
- NCT06893627 — Body Project SMIL: Prevention of Eating Disorders Among Young Women With Psychiatric Illness With the Body Project · NA · not yet recruiting
- NCT06238141 — Expressive Writing on Stress-Related and Work-Related Outcomes Among Chinese Nursing Interns · NA · completed
- NCT06872268 — APPLICATION OF THERAPEUTIC PHOTOGRAPHY AND EXPRESSIVE WRITING IN THE MANAGEMENT OF PATIENTS WITH MARFAN SYNDROME · NA · completed
- NCT06230068 — ExBRAC - the Pilot Study · NA · completed
- NCT05863598 — Prevention of Eating Disorders Through Optimization of Protective Factors · NA · recruiting
Other recruiting trials for Major Depression
Currently open trials in the same condition.
- NCT07031817 — Validation of a Composite Medical Device Using a Blood Biomarker-based Algorithm and MDQ for the Diagnosis of Bipolar Di · NA · recruiting
- NCT07184697 — Efficacy and Safety of Task-specific, Biomarker-driven, HD-ctACS inTRD. · NA · active not recruiting
- NCT07463911 — Treatment Response In ECT Patients · active not recruiting
- NCT06763081 — Pharmacogenomics of Selective Serotonin Reuptake Inhibitor (SSRI)-Induced Behavioural Activation · recruiting
- NCT06781593 — Combining Light Therapy and CPAP in Depression · NA · recruiting
Other Centre for Addiction and Mental Health trials
Trials by the same sponsor.
- NCT07211438 — Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression · Phase 2 · not yet recruiting
- NCT07146633 — Efficacy of an EMDR App for PTSD and SUD · NA · recruiting
- NCT07228923 — Development and Evaluation of a Theory and Evidence-based Intervention to Reduce Hazardous Alcohol Consumption Among Tre · NA · not yet recruiting
- NCT07105449 — THC Titration of High-Potency Cannabis Concentrates · NA · not yet recruiting
- NCT06928935 — Digital Dialectical Behavioural Therapy (d-DBT) for Youth at Clinical High Risk (CHR) for Psychosis · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06699719 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre for Addiction and Mental Health
- Last refreshed: 21 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06699719.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing